Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Uterine Cervical Dysplasia 1Sexually Transmitted Diseases, Viral 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neuroblastoma 1Head and Neck Neoplasms 1

Interventions

Cisplatin 43Radiotherapy 27Radiotherapy, Intensity-Modulated 24Radiation 16Carboplatin 14Surveys and Questionnaires 13Magnetic Resonance Spectroscopy 13Cetuximab 11Surgical Procedures, Operative 10pembrolizumab 9Specimen Handling 8Chemoradiotherapy 8Drug Therapy 7Docetaxel 7Biopsy 71,2-diaminocyclohexaneplatinum II citrate 7Platinum 6Paclitaxel 6Fluorouracil 6durvalumab 5X-Rays 5Observation 5Blood Specimen Collection 5Standard of Care 4Nivolumab 4Immunohistochemistry 4Celecoxib 4Taxes 3Neck Dissection 3Liquid Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Oropharyngeal Neoplasms × Vaccines, DNA × Clear all
NCT05799144 2025-10-22

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
54 enrolled
Head & Neck

Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡